Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
PharmiWeb,
: Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products…
: Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products…
(GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National…
(GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National…
(GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National…